Diary - News
All news ERYTECH COLLABORATES WITH FOX CHASE CANCER CENTER TO ADVANCE ITS PLATFORM IN THE FIELD OF RARE METABOLIC DISORDERS
ERYTECH 
Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company’s erymethionase program for homocystinuria, a rare and severe metabolic disorder of methionine metabolism.
The collaboration will leverage FCCC’s world-class expertise to generate in vivo proof-of-concept data with erymethionase in a homocystinuria animal model.
